American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Successful Engraftment in Patients with Active R/R AML After Personalized Iodine-131-Apamistamab, an Anti-CD45 Radioimmunotherapy

ASH 2020 – AML

Among patients with relapsed/refractory acute myeloid leukemia (R/R AML), patient-specific doses of iodine-131-apamistamab resulted in consistent engraftment following allogeneic hematopoietic stem-cell transplantation. Read More ›

A Phase 3 Comparison of Azacitidine ± Gilteritinib for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Patients

ASH 2020 – AML

No new safety signals associated with gilteritinib were found in a study comparing gilteritinib + azacitidine with azacitidine alone in patients with newly diagnosed, FLT3-mutated AML. A composite response rate of 67% was found among patients in the safety cohort receiving gilteritinib + azacitidine. Read More ›

APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM

ASH 2020 – Multiple Myeloma

Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab + Pd reduced the risk for disease progression and death without additional safety signals for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor. Read More ›

Lisocabtagene Maraleucel in High-Risk and Pretreated Patients with Relapsed or Refractory CLL

ASH 2020 – CLL: Wrap-Up

In pretreated, high-risk patients with relapsed or refractory chronic lymphocytic leukemia (CLL), treatment with lisocabtagene maraleucel (liso-cel) resulted in a high rate of undetectable minimal residual disease. Responses to treatment with liso-cel were rapid and durable, without late or delayed adverse events of concern. Read More ›

LOXO-305 in Previously Treated CLL/SLL: Safety and Early Efficacy Data from the BRUIN Trial

ASH 2020 – CLL: Wrap-Up

The noncovalent BTK inhibitor LOXO-305 demonstrated promising efficacy in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LOXO-305 was well-tolerated and active in patients following multiple prior lines of therapy, including patients with and without BTK C481 mutations. Read More ›

CPX-351 plus Venetoclax in Patients with Acute Myeloid Leukemia: A Phase 2 Study

ASH 2020 – AML

CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity in patients with relapsed/refractory acute myeloid leukemia. Read More ›

Safety and Efficacy of CD19-CAR T-Cells in Richter’s Transformation Following Targeted Therapy for CLL

ASH 2020 – CLL: Wrap-Up

Treatment with CD19-CAR T-cells in patients with chronic lymphocytic leukemia (CLL) and disease transformation was found to be safe and demonstrates a high rate of complete remission. Read More ›

Treating First AML Low Blast Count Relapse with Escalated Dosing Schedules of CC-486 Is Effective and Well-Tolerated

ASH 2020 – AML

An escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients with acute myeloid leukemia (AML) who relapsed with 5% to 15% blasts on-study in the QUAZAR AML-001 trial. Read More ›

Umbralisib plus Ublituximab in Patients with Treatment-Naïve and Relapsed or Refractory CLL

ASH 2020 – CLL: Wrap-Up

The combination of umbralisib and ublituximab, referred to as U2, was well-tolerated and significantly improved progression-free survival when compared with standard of care in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). Read More ›

A Comparison of the Effectiveness of Glasdegib versus Venetoclax in Combination with Low-Dose Ara-C

ASH 2020 – AML

Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC. Read More ›

American Society of Hematology (ASH)

Page 9 of 44